<SEC-DOCUMENT>0001193125-15-060074.txt : 20150224
<SEC-HEADER>0001193125-15-060074.hdr.sgml : 20150224
<ACCEPTANCE-DATETIME>20150224162705
ACCESSION NUMBER:		0001193125-15-060074
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150219
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150224
DATE AS OF CHANGE:		20150224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MYRIAD GENETICS INC
		CENTRAL INDEX KEY:			0000899923
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				870494517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26642
		FILM NUMBER:		15643826

	BUSINESS ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108

	MAIL ADDRESS:	
		STREET 1:		320 WAKARA WAY
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84108
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d879419d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;19, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MYRIAD GENETICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-26642</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>87-0494517</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>320 Wakara Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Salt Lake City, Utah 84108 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (801)&nbsp;584-3600 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;19, 2015, the Board of Directors of Myriad Genetics,
Inc. (&#145;Myriad&#148; or the &#147;Company&#148;) authorized an additional $200 million stock repurchase program which the Company announced on February&nbsp;24, 2015 attached hereto as Exhibit 99.1. The press release is hereby incorporated by
reference into this Item&nbsp;8.01 of this Current Report on Form 8-K and is being filed pursuant to Item&nbsp;8.01. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or
privately negotiated transactions as determined by the Company&#146;s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and
other factors. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENT AND EXHIBITS. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated February 24, 2015.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MYRIAD GENETICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;24, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter D. Meldrum</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Peter D. Meldrum</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT INDEX </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated February 24, 2015.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d879419dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:22pt">
<TD VALIGN="top">


<IMG SRC="g879419snap2.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ALIGN="right">News Release</TD></TR>
</TABLE> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media&nbsp;Contact:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Ron Rogers</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Investor Contact:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Scott Gleason</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">(801) 584-3065</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">(801) 584-1143</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><U>rrogers@myriad.com</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"><U>sgleason@myriad.com</U></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Myriad Board Approves $200 Million Increase in Share Repurchase Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SALT LAKE CITY, Utah, Feb. 24, 2015 </B>&#150; Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that its board of directors has
approved an additional $200 million authorization for its share repurchase program. As of the end of the December&nbsp;31, 2014, the Company has repurchased almost $1 billion of stock since the inception of the program in 2010. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;This increase in the authorization under our share repurchase program is consistent with Myriad&#146;s long-term commitment to return
cash and deliver value to shareholders,&#148; said Bryan Riggsbee, chief financial officer, Myriad, &#147;Since the inception of the program we have repurchased over 38&nbsp;million shares of our stock and we will continue to opportunistically
repurchase shares at valuation thresholds that we believe do not reflect the long-term value of the Company and its product pipeline.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repurchases
under Myriad&#146;s share repurchase program are made via open market or privately negotiated purchases as determined by the Company&#146;s management. The amount and timing of stock repurchases will depend on business and market conditions, stock
price, trading restrictions, acquisition activity, and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Myriad Genetics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients&#146; lives through the discovery and
commercialization of transformative tests to assess a person&#146;s risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets,
diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company&#146;s website: <U>www.myriad.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Myriad, the Myriad logo, BART, BRAC<I>Analysis</I>, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung
Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements relating to the Company&#146;s long-term commitment to return cash and deliver value to shareholders through stock repurchases; the continuation of the Company opportunistically repurchasing shares at valuation thresholds that the Company
believes do not reflect the long-term value of the Company and its product pipeline; the amount, timing and manner of stock repurchases; and the Company&#146;s strategic directives under the caption &#147;About Myriad Genetics.&#148; These risks and
uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our
ability to transition from our existing to new testing services, including unexpected costs and delays; risks related to changes in the governmental or private insurers&#146; reimbursement levels for our tests or our ability to obtain reimbursement
for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional
molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our
ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or
cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to
regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections
about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the
proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading &#147;Risk Factors&#148;
contained in Item&nbsp;1A of our Annual Report on Form 10-K for the fiscal year ended June&nbsp;30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g879419snap2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g879419snap2.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`#(```("`P$```````````````,$``(!!08'`0$``P$!````
M`````````````0(#!`7_P@`1"`!:`'4#`1$``A$!`Q$!_]H`#`,!``(0`Q``
M``'JMN;2]')9-XEFFAZW-6UXM6:AM4,U7OF&U>KXO2M$\]U</)]OFPA8V.6[
MN>S5-&::4F%;Y*WSUVN'?>9[1(MSW5P\GV^;"$-AGL[GJU35JFD@K?-73)#3
M'N_-]DD6Y[JX>3[?-@:+.YZN9ZM4T+6]9A:^:6F2>F*MJ>D^3[Q(MSW5P\WU
M\#^6S=-6J:$B5[45OFIIDAIB.8A#TGR?>)%M!T\6HWY6J:-TU/6X+44ODK?/
M6[<XIB$(>D^3[Q(MSW5PZ+IXG<]FJ:,TTRE:V:NF2&F*>F52$/2?)]XD64OD
MEKB2MB1-HM>)RG"!S4=JBFN)81N>?KRE=$`!"&00R#*C:4D6&TY`(5*FS3KD
M,B4ME$KHH6,&0@PD*,IJ@R0((G"*D+I&C`1.$%3DA"$(0A"$(0A`_\0`*1``
M`@(!`P,#!`,!`````````0(``Q$$$C,%%!40$R`C,3(T(2)!,/_:``@!`0`!
M!0+6ZE],GE;IY:R#JKP=1)@UQ@U4[AH=0XAU=@AUUL/4KA/+613E9U;C]02(
MAW!<Q<P9A4QD,9#+*\1..=6X_A76<"N+7!7"L985EN`$XYU;C]!4QBT8@J@I
M$]M1#MC$1W01K!Z)QSJW&E>8H410L7;-RB-8L+B/8!"Q;X)QSJ?XAHKQ7F_^
M&>&R%XYRWP3CG5>-+HML6V"V$YC&-+$S,'X)QR_3IJ!XS3P:"D3LZYVJ3MUG
ML+.W2=I7#H*6GC-//&:>>+H@&!+MPKI?W*[K&%EV\5LV:;-R4DNM!.ZK3EFJ
MOL-8^\7<;W9Z9]_2[C)]C46C`E"XNOX&R*S^&F_7PUDTQ^FO[>I/T0PK6/7O
MA0-'J%D_Q:@CNF]16`@JPBU;$1-BK4%?V?[BL`M7D@8'_<#_Q``K$``!`@()
M!`(#`0`````````!``(1\`,$$Q0A,6&AX1`@4;$2T7&1\5#_V@`(`0,``3\!
MK%*:(8*^/\*^.\*^.\(5J*O$X_2MIQ5H9BK1TQ5LZ8_2O#O'M&M/\*^.\(8C
MI7,AVM,9*$9BA&8K&8HB<41.*+9Q3FP3<NE<R':UJ#=-N4&Z;<H-TVY1&FW*
M(TVY1&FW*>FY=*YD.OQ*%'."#)P0HQ,%\1,%A,/M&$@?:<X#^(NZ-RZ5S((!
M`"8(0F"$)@HB8(N$P1<)@BX3!$Q[&Y=*WD$#KN@[7?A!VN_"^6N_"+M=^$7:
M[\(NUG])V?:W+I7,@FO0?KN4'Z^T'Z^U'7VC^?:,YIPCVMRZ4E$VDS5THU=F
M!6#=58CR?VK(>59A605BU&K,*NE&KI1JZ4:&'^\`_\0`)1```@`$!@(#`0``
M``````````$"$3'P!!`2$Q0A(%$#06%0_]H`"`$"``$_`?B^-1OLXT)QH?9Q
ME[-@VC;-"-"-M&S"<>'V<:'V/+#5?BU(=T'="_HG?0G?0G?1"QURPU7XMC8X
MOTF3$Q,A'7+#5>>I#C-5]FN^R;N9V(28EDZY8:K&QS'.YG=S).YBA=S%#?8H
M1*7@ZY8?[&AH:_"0D)?@D+Q=<L-5CA'#?1IOHTWT2%=!"?BZY01N"AR(S?B-
MUFXS6S6:V;K-Z)'(C.1&<B/^^/_$`#`0``$"`@<'!`(#`0````````$``A$Q
M$B$R<9&2T0,004*BH^$@,U&A@;%`\?)A_]H`"`$!``8_`FE@%?RK#%8:K#5)
MOVI#[T4A@=%4!@=%)OWHK+>K16&]2]H*PU`[MG?Z*E_I2.#U(Y7J1P<I'!ZD
M<'J1P<HP^BFW;MG?Z:VG*O;Z/*]OM^58[?E6.V=58[9U5CH.JE7<FW;MG?OX
M8K^M5(8-U5EN5NJLMR-5D9&ZJR,@U58&0:JIK<NYMV[9WJLC,IC,U3;F:N7%
MJY<6KEQ8N7H7#I7##T-NW;*]6^OPO<[GA>YW/"M]?A>YW/"]SN>%;Z_'J;=N
MV=ZK<<Q5OK<K?6Y6^IRMG.Y6^MVBM=3M%/\`?I;=N`?&KX7-BJB_,K6TS*WM
M,Y5O:9RK3\Y4WYRIOSE5TLRYL5S8KFQ4-Q+70*B9\4QK3"NM4F.D@6.K,D33
M,0AM`_A(J(,*HH.<8DH4?S=N>RF8!4HTF<?03RO_`&ME&9?$[MH.#9)]RV5.
MO9\4;DU/(A1-5:HF;:EM+D1Q-036GXW5D_A"E7"M")-2FBX.,3-423!4)C_J
MH!Q@J`<8*B)(OI&)FB^FZ)49GY*C&"A_`/_$`"@0`0`"``0%!0$!`0$`````
M``$`$2$Q8?`047&AL2!!D<'1@>'Q0/_:``@!`0`!/R%AE5-8>]\#^SF]^*:2
MUMGU_P#YB/SDK!60K\*E^(P%^'XB&=KC-NRSO<OAW3T*XDCV`_RWAFVON#?/
M,#-_\S>CS-B_/`77I4-+S.U<.Z>DF-/]?<;_`*PO-\HJ]_RC#SP:N#62*AA6
ML^YVKAW3B2)@Z82O/K>#>!,8VP[Q#@ANR%R6L8=!P[5P[I`Q5.@A@;[I-@?$
M'/MZ1WOXG-;VD?\`Z_$]B_@7@F>?`'H[5PKB97]ZA^F(19&D^$;HAE;O^WZ>
MU<,-'-&J@5[I>)R7NTFKVZ0.;=I%&&PTB<T2>>0,=;YJOJ(9B>CM7#!]*RTT
M("T`T@+],"@!0-F?<6W'>+Q"*M-5-'@5J[ND`QD%<+!`RE)D<!K*@Q(NL-Y7
MG,,2*U9<5)1W=&,>(M%`IB61L%:P/0NFX"`3)B:50F4('RQ,2"`3)X9O4.\-
M#+N%;DO``O,P<KX9;E>%:JI7`RCS_,TXO017W_>=ME6=I#G,0)`01!,H1`9R
M@XYFBQA'M97.5DMUG/"5[PF`6=2REKJ"?Z'"I7JR@$BC*X).ZH$![EB2Z[YI
M<HQ9``9&'_@`_]H`#`,!``(0`Q```!#>!2PE:"#;$@"5;P;;0@;'>#:WO0`[
MP9"'XK;>;-!?G;;R$VS'G;>8YI1>\=Q__MU^-R-*9B-M_BQA@MSN.2222222
M0/_$`"@0`0`"`0(&`@(#`0$```````$`$2$Q44%A<8&A\!"1L<$@T>'Q0/_:
M``@!`0`!/Q!T.P1"@TI(/5]!@'5=/]0Z.>*@^KCE"IJ)?B=;+H\:*$QJQU/X
M,[2FDT%Y7@&.`J_=,>"77_4<$":#F?'J-C^%PW2FKA]C@@H[P&%+WIP)6N4=
MN'GJ]HR8C(/L_:Q+MB(`ZW'NMCX]1L?Q!6!O*\Z1U4ONC"E6%U1J4DTSYHS+
MOZF$]>D%/7*GNMCX]1L?%0(;,Y%\LJ94E52\Q67WW@^J=R`,@QDT=N3(N3K<
MIIG_``HJE(U4^%G&>ZV/CU&Q`BYF"R=;@U$-+9\Q@YYQ`OW\ET,8&@2:8KO2
M#:UX)345%>P!\FL]UL?&M:R'0P<<U#;/K`%8$QQ^V=CWZSJZ.V=:!OO![T.[
M'@>!UH_@:SW6Q\-6D1A.&"(",9L'E,0I/724Q<6XI@[10Z,Y,8B[?OPR&CJC
M3;,BV)S/DUGNMCXSA%@-8'Q?7*$SK00":"70_P!S1Q]MYH?K<YO+U@U>*UWV
M.<LOMD'F/`+WRBFE.S^I_P`=%XU(7L?%17X`(M\;(XZG=L-8MPYP4X`OD+W(
MF#*Z%O<-9A45<6KOCAF^D+?9KD=*A>'DP*O0$UF+[I*4Q?&7"UU`"E,42X0"
MO@$'[LCEV%CN3!4L%L\ZE;(0`+^(FOU'+L+'<^%0;_>,M1&X\!_?[GD_$>';
M!VG*-4U[M-9KZ)YN.DJ1X`JZU+_$:9#95:54\7\DLW]M!O(65SMCS6X=-/'X
MGL>4`,M@ZJR7&+%;U41BT6.Y!0M&P,C8Z07%GJ%G2'X"-@`XZ09G&JM5]8HF
MEV">$PL4#"SZG".JAQMB`AK!D4;#6D6<#<+W4U,1&<-AV)P%0*5LQ4#A*D9#
MI4#U,HL`Y;=H3*"."\G$YP':$!R/_`#_Q``G$``"``0&`@,!`0$`````````
M`1$QD=$005%QH?`A82"QX<'Q0/_:``@!`P`!/Q!,:KSJ>AS<];D3'Y3D9D7-
MA,\D"9Y<6$:4*6#5DNMAJR0-.3K83?[/6Y'@/#G?!-J0Q(KJIZ'2\30Z7B6A
MTO&Z<7C=.+QFG!A(I</^DG;#G?%Z7E<?J&X!$']!U,.IAU,&24(<-?TD[8<[
M%.E]H4NW"=%2XT"I<).2I<-IDJ`VA`F25%Q,?"5,).V'.%ORVJH44(JM@FI5
MM$]*VC7I6T]*MIZ7>PMVP;-]?"3MAF=3J_&(`28@`.AAH_%)VP\-X;F^6=%@
MZ'8=#L'%+E8,_P#5@SUYL)Z/W8@U\).V"%+*;M1>(FZL2\ZF)-P)&:K/8ZNX
MVYNKN-^;J[G@G&K-VIO5-ZHD"2P8O(V,R'(RP0W##,EBR3'@ARQ4B8C,<B6$
M,(80AA`@0@2($"!#_A#_Q``G$``"``,(`P$``P```````````1&AT1`Q05%A
MD>'P("%QP4"Q\?_:``@!`@`!/Q!R6`U6:@:5Z8:K%RJ-5C_51JNJI"O_`"HG
MXN51/Q<JB9BY5$W_``:@2#:\@TG>1D*4(.N@@SG0-K.=`DS"<PC.8B^FYK\+
M[S"X^G/@3G/@Z'P/7/@6J:H:DU0U)JA[./[P7WB&CK(G70;YSH&V;WH(V,Z!
M18S=!'G-T'KG-T&XM[V7UH8KE(9L).HVK:H;U;5"9GM4:C:H9KU]&/KJ(N>%
M]9>&A+DT9<G4N3YER:,N3J7)HRY%@O&^M&6I(T95#TRJ'!A*H4&$E4192J$6
M4E4A>J5(KPOK&[9^&PVWI;&FMD:2V1I+9$62V1"P6R$G+9"NT-CX;'R/D-Q<
D;$/T(5B,;&)68%]J+T*QBOM=Y<,P%;=9&%D2ZR)&R)'^'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
